What is Filgrastim-Teva 30 Mio E/0.5ml?
Filgrastim-Teva 30 Mio E/0.5ml injection is used to treat neutropenia (low white blood cells) that is caused by cancer medicines. It is a synthetic (man-made) form of a substance that is naturally produced in your body called a colony stimulating factor. Filgrastim-Teva 30 Mio E/0.5ml helps the bone marrow to make new white blood cells.
When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Filgrastim-Teva 30 Mio E/0.5ml is used to prevent or reduce the risk of infection while you are being treated with cancer medicines. Filgrastim-Teva 30 Mio E/0.5ml is also used to help the bone marrow recover after a bone marrow transplantation, for a process called peripheral blood progenitor cell collection in cancer patients, and to improve survival in cancer patients who have been exposed to radiation.
Filgrastim-Teva 30 Mio E/0.5ml is available only with your doctor's prescription.
Filgrastim-Teva 30 Mio E/0.5ml indications
Established Cytotoxic Chemotherapy: Filgrastim-Teva 30 Mio E/0.5ml is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation.
Peripheral Blood Progenitor Cell Mobilization (PBPC): Filgrastim-Teva 30 Mio E/0.5ml is indicated for the mobilization of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy in order to accelerate hematopoetic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. The safety and efficacy of Filgrastim-Teva 30 Mio E/0.5ml are similar in adults and children receiving cytotoxic chemotherapy. Filgrastim-Teva 30 Mio E/0.5ml is indicated for the mobilization of peripheral blood progenitor cells in normal volunteers for use in allogeneic peripheral blood progenitor cell transplantation.
Severe Chronic Neutropenia (SCN): In patients, children or adults, with severe congenital, cyclic or idiopathic neutropenia with an ANC of ≤0.5x109/L, and a history of severe or recurrent infections, long-term administration of Filgrastim-Teva 30 Mio E/0.5ml is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
HIV Infection: Filgrastim-Teva 30 Mio E/0.5ml is indicated for the treatment of persistent neutropenia (ANC ≤1.0 x 109/L) in patients with advanced HIV infection, in order to reduce risk of bacterial infections, when other options to manage neutropenia are inappropriate.
Patients with Acute Myeloid Leukemia (AML): Filgrastim-Teva 30 Mio E/0.5ml is indicated to reduce the duration of neutropenia and related clinical sequelae in patients undergoing induction or consolidation chemotherapy.
How should I use Filgrastim-Teva 30 Mio E/0.5ml?
Use Filgrastim-Teva 30 Mio E/0.5ml as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Filgrastim-Teva 30 Mio E/0.5ml. Talk to your pharmacist if you have questions about this information.
- Do not shake Filgrastim-Teva 30 Mio E/0.5ml. Shaking may damage Filgrastim-Teva 30 Mio E/0.5ml. If the vial or syringe has been shaken, the solution may appear foamy and should not be used.
- Filgrastim-Teva 30 Mio E/0.5ml is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Filgrastim-Teva 30 Mio E/0.5ml at home, a health care provider will teach you how to use it. Be sure you understand how to use Filgrastim-Teva 30 Mio E/0.5ml. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Do not use Filgrastim-Teva 30 Mio E/0.5ml if it contains particles, is cloudy or discolored, or if the vial or syringe is cracked or damaged.
- Use only disposable syringes and needles. Use the syringes and needles only once and dispose of them in a puncture-proof container as instructed by your health care provider.
- Choose a new site each time you inject Filgrastim-Teva 30 Mio E/0.5ml. Do not inject into an area that is tender, red, bruised, hard, swollen, or has scars or stretch marks.
- Discard any unused portion of medicine left in the vial or syringe.
- Continue to use Filgrastim-Teva 30 Mio E/0.5ml for the full course of treatment. Do not miss any doses.
- Filgrastim-Teva 30 Mio E/0.5ml works best if it is used at the same time each day.
- If you use Filgrastim-Teva 30 Mio E/0.5ml because you also receive chemotherapy, the last dose of Filgrastim-Teva 30 Mio E/0.5ml should be used at least 24 hours before your next dose of chemotherapy.
- Keep this product, as well as syringes and needles, out of the reach of children and away from pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- If you miss a dose of Filgrastim-Teva 30 Mio E/0.5ml, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Filgrastim-Teva 30 Mio E/0.5ml.
Uses of Filgrastim-Teva 30 Mio E/0.5ml in details
Use: Labeled Indications
Chemotherapy-induced myelosuppression in nonmyeloid malignancies:
Filgrastim-Teva 30 Mio E/0.5ml and Filgrastim-Teva 30 Mio E/0.5ml biosimilars: To decrease the incidence of infection (neutropenic fever) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a significant incidence of severe neutropenia with fever
Tbo-Filgrastim-Teva 30 Mio E/0.5ml: To decrease the duration of severe neutropenia in adult and pediatric patients ≥1 month of age with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of neutropenic fever
Acute myeloid leukemia (AML) following induction or consolidation chemotherapy (Filgrastim-Teva 30 Mio E/0.5ml and Filgrastim-Teva 30 Mio E/0.5ml biosimilars): To reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy in adults with AML
Bone marrow transplantation (Filgrastim-Teva 30 Mio E/0.5ml and Filgrastim-Teva 30 Mio E/0.5ml biosimilars): To reduce the duration of neutropenia and neutropenia-related events (eg, neutropenic fever) in patients with nonmyeloid malignancies receiving myeloablative chemotherapy followed by marrow transplantation
Hematopoietic radiation injury syndrome, acute (Filgrastim-Teva 30 Mio E/0.5ml only): To increase survival in patients acutely exposed to myelosuppressive doses of radiation
Peripheral blood progenitor cell collection and therapy (Filgrastim-Teva 30 Mio E/0.5ml and Filgrastim-Teva 30 Mio E/0.5ml biosimilars): Mobilization of autologous hematopoietic progenitor cells into the peripheral blood for apheresis collection
Severe chronic neutropenia (Filgrastim-Teva 30 Mio E/0.5ml and Filgrastim-Teva 30 Mio E/0.5ml biosimilars): Long-term administration to reduce the incidence and duration of neutropenic complications (eg, fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic, or idiopathic neutropenia
Note: Filgrastim-Teva 30 Mio E/0.5ml (Filgrastim-Teva 30 Mio E/0.5ml-aafi) and Zarxio (Filgrastim-Teva 30 Mio E/0.5ml-sndz) are approved as biosimilars to Filgrastim-Teva 30 Mio E/0.5ml (Filgrastim-Teva 30 Mio E/0.5ml). In Canada, Grastofil is a biosimilar to Filgrastim-Teva 30 Mio E/0.5ml (Filgrastim-Teva 30 Mio E/0.5ml).
Off Label Uses
Alcoholic hepatitis (severe)
Data from a small randomized, non-blinded pilot study suggest Filgrastim-Teva 30 Mio E/0.5ml may be safe and effective therapy and may improve liver function as well as survival in patients with severe alcoholic hepatitis.
Filgrastim-Teva 30 Mio E/0.5ml description
Each powder for injection contains Filgrastim 30 MU and 48 MU.
It also contains the following excipients: Sodium acetate trihydrate, mannitol and polysorbate 80.
Filgrastim-Teva 30 Mio E/0.5ml 30 MU Lyophilized Powder for Injection: Each vial of solvent contains benzyl alcohol 9 mg/mL.
Filgrastim-Teva 30 Mio E/0.5ml 48 MU Lyophilized Powder for Injection: Each vial of solvent contains benzyl alcohol 14.4 mg/1.6 mL.
The reconstituted preparation with 1 mL solvent (containing benzyl alcohol 0.9%) results in a clear, colorless solution.
Each vial of 1 mL and 1.6 mL solution for injection contains Filgrastim 30 MU and 48 MU, respectively.
It also contains the following excipients: Sodium acetate trihydrate, polysorbate 80, benzyl alcohol and water for injection.
Each pre-filled syringe of 0.5 mL and 0.8 mL contains Filgrastim 30 MU and 48 MU, respectively.
It also contains the following excipients: Sodium acetate trihydrate, polysorbate 80, benzyl alcohol and water for injection.
Filgrastim-Teva 30 Mio E/0.5ml (recombinant human granulocyte-colony stimulating factor, rH G-SCF) is produced by r-DNA technology in Escherichia coli.
Filgrastim-Teva 30 Mio E/0.5ml dosage
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Injection:
Filgrastim-Teva 30 Mio E/0.5ml: Filgrastim-Teva 30 Mio E/0.5ml 300 mcg/mL (1 mL); Filgrastim-Teva 30 Mio E/0.5ml 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]
Solution, Injection [preservative free]:
Filgrastim-Teva 30 Mio E/0.5ml: Filgrastim-Teva 30 Mio E/0.5ml-aafi 300 mcg/mL (1 mL); Filgrastim-Teva 30 Mio E/0.5ml-aafi 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]
Solution, Subcutaneous [preservative free]:
Granix: tbo-Filgrastim-Teva 30 Mio E/0.5ml 300 mcg/mL (1 mL); tbo-Filgrastim-Teva 30 Mio E/0.5ml 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]
Solution Prefilled Syringe, Injection [preservative free]:
Filgrastim-Teva 30 Mio E/0.5ml: Filgrastim-Teva 30 Mio E/0.5ml 300 mcg/0.5 mL (0.5 mL); Filgrastim-Teva 30 Mio E/0.5ml 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]
Filgrastim-Teva 30 Mio E/0.5ml: Filgrastim-Teva 30 Mio E/0.5ml-aafi 300 mcg/0.5 mL (0.5 mL); Filgrastim-Teva 30 Mio E/0.5ml-aafi 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]
Zarxio: Filgrastim-Teva 30 Mio E/0.5ml-sndz 300 mcg/0.5 mL (0.5 mL); Filgrastim-Teva 30 Mio E/0.5ml-sndz 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]
Solution Prefilled Syringe, Subcutaneous [preservative free]:
Granix: tbo-Filgrastim-Teva 30 Mio E/0.5ml 300 mcg/0.5 mL (0.5 mL); tbo-Filgrastim-Teva 30 Mio E/0.5ml 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]
Dosing: Adult
Note: Do not administer in the period 24 hours before to 24 hours after cytotoxic chemotherapy. May round the dose to the nearest vial size for convenience and cost minimization (ASCO [Ozer 2000]). Filgrastim-Teva 30 Mio E/0.5ml (Filgrastim-Teva 30 Mio E/0.5ml-aafi) and Zarxio (Filgrastim-Teva 30 Mio E/0.5ml-sndz) are approved as biosimilars to Filgrastim-Teva 30 Mio E/0.5ml (Filgrastim-Teva 30 Mio E/0.5ml). In Canada, Grastofil is a biosimilar to Filgrastim-Teva 30 Mio E/0.5ml (Filgrastim-Teva 30 Mio E/0.5ml). International considerations: Dosages below expressed as micrograms; 1 mcg = 100,000 units (Hoglund 1998).
Acute myeloid leukemia (AML) following induction or consolidation chemotherapy (Filgrastim-Teva 30 Mio E/0.5ml and Filgrastim-Teva 30 Mio E/0.5ml biosimilars): SubQ, IV: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the ANC reaches 10,000/mm (Díaz 2000; Wagner 2001).
Filgrastim-Teva 30 Mio E/0.5ml interactions
See also:
What other drugs will affect Filgrastim-Teva 30 Mio E/0.5ml?
The safety and efficacy of Filgrastim-Teva 30 Mio E/0.5ml given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, the use of Filgrastim-Teva 30 Mio E/0.5ml is not recommended in the period from 24 hrs before to 24 hrs after chemotherapy. Preliminary evidence from a small number of patients treated concomitantly with Filgrastim-Teva 30 Mio E/0.5ml and 5-fluorouracil indicate that the severity of neutropenia may be exacerbated. Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical trials.
Since lithium promotes the release of neutrophils, lithium is likely to potentiate the effect of Filgrastim-Teva 30 Mio E/0.5ml. Although this interaction has not been formally investigated, there is no evidence that such an interaction is harmful.
Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone-imaging changes. This should be considered when interpreting bone-imaging results.
Incompatibilities: Filgrastim-Teva 30 Mio E/0.5ml should not be diluted with saline solutions. If required, Filgrastim-Teva 30 Mio E/0.5ml may be diluted in 5% glucose.
Diluted Filgrastim-Teva 30 Mio E/0.5ml may be adsorbed to glass and plastic materials. However, when diluted in 5% glucose solution, Filgrastim-Teva 30 Mio E/0.5ml is compatible with glass and a variety of plastic including PVC, polyolefin (a copolymer of polypropylene and polyethylene) and polypropylene.
Filgrastim-Teva 30 Mio E/0.5ml side effects
See also:
What are the possible side effects of Filgrastim-Teva 30 Mio E/0.5ml?
Filgrastim-Teva 30 Mio E/0.5ml usually does not cause serious or life-threatening adverse effects and it only rarely has required discontinuance. Because most patients who receive Filgrastim-Teva 30 Mio E/0.5ml have recently undergone cytotoxic chemotherapy, many of the adverse effects reported with Filgrastim-Teva 30 Mio E/0.5ml therapy may actually result from the actions of the previously administered antineoplastic agents.
The most frequent adverse effect reported during Filgrastim-Teva 30 Mio E/0.5ml therapy is deep, throbbing medullary bone pain, most often in the lower back, pelvis, ribs or sternum (eg, sites containing bone marrow). Sternal pain can imitate the pain of an acute myocardial infarction. The severity of the pain usually is increased in patients with more extensive leukocytosis. Non-opiate analgesics can alleviate this effect, and bone pain may spontaneously resolve with continued therapy.
Dose- or route-dependent, Filgrastim-Teva 30 Mio E/0.5ml-induced leukocytosis (leukocyte count >100,000/mm3) can occur during therapy, and the drug should be discontinued if the absolute neutrophil count (ANC) rises >10,000/mm3 after the nadir is achieved. An ANC >10,000/mm3 will not increase the effectiveness of the drug, but can increase its toxicity.
Splenomegaly has been observed in both children and adults during therapy with Filgrastim-Teva 30 Mio E/0.5ml, but is not common.
Filgrastim-Teva 30 Mio E/0.5ml contraindications
See also:
What is the most important information I should know about Filgrastim-Teva 30 Mio E/0.5ml?
You should not use this medication if you are allergic to Filgrastim-Teva 30 Mio E/0.5ml or to other medicines that contain the E. coli bacteria.
Before using Filgrastim-Teva 30 Mio E/0.5ml, tell your doctor if you have a blood cell disorder (such as sickle cell anemia), chronic myeloid leukemia, myelodysplasia (also called "preleukemia"), or if you are receiving chemotherapy or radiation treatment.
Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles, syringes, IV tubing, and other items used to inject the medicine.
To be sure this medication is helping your condition, your blood may need to be tested often. This will help your doctor determine how long to treat you with Filgrastim-Teva 30 Mio E/0.5ml. Your liver function will also need to be tested, and you may need bone density scans. Visit your doctor regularly.
Stop using Filgrastim-Teva 30 Mio E/0.5ml and call your doctor at once if you have a serious side effect such as sudden or severe pain in your left upper stomach spreading up to your shoulder, rapid breathing or feeling short of breath, or signs of infection (fever, chills, sore throat, flu symptoms, easy bruising or bleeding, loss of appetite, nausea and vomiting, mouth sores, or unusual weakness).
Active ingredient matches for Filgrastim-Teva 30 Mio E/0.5ml:
Filgrastim in Switzerland.
List of Filgrastim-Teva 30 Mio E/0.5ml substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Filgrastim-Teva 48 Mio E/0.8ml (Switzerland) | |
| Filgrastima (Brazil) | |
| Filgrastine (Brazil) | |
| Filgratech (Peru) | |
| Fillif (India) | |
| Fillif 300mcg/mL INJ / 1 (Torrent) | $ 32.46 |
| FILLIF 300MCG PREFILLED SYRINGE 1 packet / 1 ML prefilled syringe each (Torrent) | $ 14.01 |
| FILLIF inj 300 mcg x 1 mL x 1ml (Torrent) | $ 32.46 |
| Fillif 300mcg Prefilled Syringe (Torrent) | $ 14.01 |
| FILNIM | |
| FILNIM 300MG INJECTION 1 vial / 1 injection each (Fourrts India Laboratories Pvt Ltd) | $ 30.00 |
| Finabold | |
| Finabold 1 mg Tablet (East West Pharma) | $ 0.04 |
| Foltran (Chile) | |
| Frastim (India) | |
| Frastim 300mcg/0.5ml PFS / 1 (RPG Life Sciences Ltd) | $ 31.93 |
| 300 mcg x 0.5 mL x 1's (RPG Life Sciences Ltd) | $ 31.93 |
| Frastim 300 mcg Injection (RPG Life Sciences Ltd) | $ 0.02 |
| FRASTIM 300MCG PREFILLED SYRINGE 1 packet / 1 ML prefilled syringe each (RPG Life Sciences Ltd) | $ 33.89 |
| FRASTIM inj 300 mcg x 0.5 mL x 0.5ml (RPG Life Sciences Ltd) | $ 31.93 |
| Frastim 300mcg Prefilled Syringe (RPG Life Sciences Ltd) | $ 33.89 |
| Fraven (Turkey) | |
| G CYTE | |
| G-CSF V y T Farma (Paraguay) | |
| Grafeel (India, Vietnam) | |
| Grafeel 300ncg VIAL / 1 (Dr Reddy Laboratories Ltd) | $ 31.12 |
| 300 mcg x 1's (Dr Reddy Laboratories Ltd) | $ 31.12 |
| Grafeel 300 mcg/1 mL x 1 Bottle 1 mL (Dr Reddy Laboratories Ltd) | |
| Grafeel 300 mcg Injection (Dr Reddy Laboratories Ltd) | $ 0.02 |
| GRAFEEL 300 MCG INJECTION 1 vial / 1 ML injection each (Dr Reddy Laboratories Ltd) | $ 27.10 |
| GRAFEEL 300 MCG PREFILLED SYRINGE 1 packet / 1 prefilled syringe each (Dr Reddy Laboratories Ltd) | $ 27.11 |
| GRAFEEL inj 300 mcg x 1ml (Dr Reddy Laboratories Ltd) | $ 32.46 |
| Grafeel 300mcg Injection (Dr Reddy Laboratories Ltd) | $ 27.10 |
| Grafeel 300mcg Prefilled Syringe (Dr Reddy Laboratories Ltd) | $ 16.80 |
| Grafeel PFS (India) | |
| Grafeel PFS 300mcg/ml PFS / 1 (Dr Reddy Laboratories Ltd) | $ 32.46 |
| 300 mcg x 1 mL x 1's (Dr Reddy Laboratories Ltd) | $ 32.46 |
| Grafeel PFS 300 mcg Injection (Dr Reddy Laboratories Ltd) | $ 0.02 |
| GRAFEEL PFS inj 300 mcg x 1 mL x 1ml (Dr Reddy Laboratories Ltd) | $ 32.46 |
| Gran (China, Japan, Malaysia, Singapore, Thailand) | |
| Gran / pre-filled syringe 30 MU/0.5 mL x 1's (Glyco Labs.) | |
| Gran 300 mcg/0.5 mL x 1's (Glyco Labs.) | |
| Gran 300 mcg/0.5 mL x 5's (Glyco Labs.) | |
| Gran 30 MU/0.5 mL x 1's (Glyco Labs.) | |
| Gran 30 MU/0.5 mL x 1 bГґm tieГўm Г±oГ№ng saГјn 0.5 mL (Glyco Labs.) | |
| Gran 150 mg Tablet (Glyco Labs.) | $ 0.01 |
| Gran inj 300 mcg/0.5 mL 0.5 mL x 1's (Glyco Labs.) | |
| GRANFILL | |
| GRANFILL 300MG INJECTION 1 vial / 1 ML injection each (Samarth Life Sciences Pvt Ltd) | $ 4.82 |
| Granogen | |
| Injectable; Injection; Filgrastim 30 MIU | |
See 410 substitutes for Filgrastim-Teva 30 Mio E/0.5ml | |
Reviews
The results of a survey conducted on ndrugs.com for Filgrastim-Teva 30 Mio E/0.5ml are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Filgrastim-Teva 30 Mio E/0.5ml. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yet1 consumer reported time for results
To what extent do I have to use Filgrastim-Teva 30 Mio E/0.5ml before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 5 days and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Filgrastim-Teva 30 Mio E/0.5ml. To get the time effectiveness of using Filgrastim-Teva 30 Mio E/0.5ml drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 5 days | 1 | 100.0% | |
Consumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
